PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Lung Cancer: Targets and Therapy10.2147/lctt.s99303201683Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectivesMarie Wislez, Etienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranelhttps://www.dovepress.com/getfile.php?fileID=30953
10.21203/rs.3.rs-264534/v12021Cost effectiveness of ceritinib in patients previously treated with crizotinib and chemotherapy with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United StatesYichen Zhang, Yixue Shao, Charles Stoecker, Lizheng Shihttps://www.researchsquare.com/article/rs-264534/v1, https://www.researchsquare.com/article/rs-264534/v1.html
PLoS ONE10.1371/journal.pone.01140082014912e114008Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer PatientsYabing Cao, Guangli Xiao, Xibin Qiu, Sheng Ye, Tongyu Linhttp://dx.plos.org/10.1371/journal.pone.0114008
Cancer Research and Treatment10.4143/crt.2017.2802018503691-700Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mokhttp://e-crt.org/upload/pdf/crt-2017-280.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.280, http://www.e-crt.org/upload/pdf/crt-2017-280.pdf
Value in Health10.1016/j.jval.2014.03.4332014173A74Estimating the Budget Impact of Crizotinib for Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in ArgentinaB. Wang, W. Furnback, J. Xuanhttps://api.elsevier.com/content/article/PII:S1098301514004847?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301514004847?httpAccept=text/plain
Current Oncology10.3747/co.25.3723201825140-49Real-World Outcomes in Patients with Alk-Positive Non-Small Cell Lung Cancer Treated with CrizotinibK.L. Davis, J.A. Kaye, E.T. Masters, S. Iyerhttp://current-oncology.com/index.php/oncology/article/viewFile/3723/2645, http://current-oncology.com/index.php/oncology/article/viewFile/3723/2615, https://www.mdpi.com/1718-7729/25/1/3723/pdf
Clinical Lung Cancer10.1016/j.cllc.2013.12.0042014153e33-e35Successful Crizotinib Rechallenge After Crizotinib-Induced Interstitial Lung Disease in Patients With Advanced Non–Small-Cell Lung CancerNobuhiro Asai, Etsuro Yamaguchi, Akihito Kubohttps://api.elsevier.com/content/article/PII:S1525730413002611?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730413002611?httpAccept=text/plain
Cancer10.1002/cncr.2847820131205664-674Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinibEvelyn M. Brosnan, Andrew J. Weickhardt, Xian Lu, Delee A. Maxon, Anna E. Barón, Michel Chonchol, D. Ross Camidgehttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.28478, https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.28478
Respirology10.1111/resp.13420_550201823288-289FACTORS ASSOCIATED WITH CRIZOTINIB EFFICACY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING DIFFERENT ALK FUSION VARIANTShttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fresp.13420_550, http://onlinelibrary.wiley.com/wol1/doi/10.1111/resp.13420_550/fullpdf
BMC Cancer10.1186/s12885-016-2636-z2016161Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancerBrian Won, Isa Mambetsariev, Ravi Salgiahttp://link.springer.com/content/pdf/10.1186/s12885-016-2636-z.pdf, http://link.springer.com/article/10.1186/s12885-016-2636-z/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12885-016-2636-z, http://link.springer.com/content/pdf/10.1186/s12885-016-2636-z.pdf